Innovative Biotherapies, Inc.

Ann Arbor, MI 48108

SBIR Award Summary

Total Number of Awards 19
Total Value of Awards $8.63MM
First Award Date 05/02/06
Most Recent Award Date 08/15/15

Key Personnel

Last Name Name Awards Contact
Buffington Deborah A Buffington 12
Westover Angela J Westover 4
Smith Peter L Smith 1
JOHNSTON KIMBERLY ANNE JOHNSTON 1
PINO CHRISTOPHER PINO 1

19 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 08/15/15 - 07/31/16

DESCRIPTION (provided by applicant): Cardiovascular disease is the leading cause of mortality in the US, accounting for 45% of all deaths. Chronic Heart Failure (CHF) is now understood to be a multi-system disease process which involves not only the cardiovascular system but also the renal, neuroendocrine and immune systems. There is no effecti...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 08/01/15 - 07/31/16

DESCRIPTION (provided by applicant): The Selective Cytopheretic Device (SCD) is an extracorporeal medical device targeted to treat patients with inflammatory disease indications. As patient blood passes through the SCD, it comes in contact with the hemocompatible fibers inside the SCD. These fibers are capable of immunomodulatory interactions wi...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 04/01/15 - 03/31/16

DESCRIPTION (provided by applicant): The Problem: Cardiovascular disease is the leading cause of death in the Western world. In the US, nearly 500,000 coronary artery bypass surgeries are performed annually with an estimated 89% of these using the technique of cardiopulmonary bypass (CPB). CPB patients experience complications, many of which are...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 07/20/13 - 07/19/14

DESCRIPTION (provided by applicant): The Problem: The lack of devices specifically designed for pediatric applications has been recognized by directives in the Pediatric Medical Device Safety and Improvement Act of 2007, included in Public Law 110-85, and the Institutes of Medicine, which has recommended pediatric studies to begin at the end of ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 06/01/13 - 05/31/14

DESCRIPTION (provided by applicant): Leukocytes (LE) are major contributors to the pathogenesis and progression of many clinical inflammatory disorders, including the systemic inflammatory response syndrome, sepsis and acute respiratory distress syndrome. The need for new and innovative therapies to treat these inflammatory disease states presen...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 09/08/12 - 05/31/13

DESCRIPTION (provided by applicant): Leukocytes (LE) are major contributors to the pathogenesis and progression of many clinical inflammatory disorders, including the systemic inflammatory response syndrome, sepsis and acute respiratory distress syndrome. The need for new and innovative therapies to treat these inflammatory disease states presen...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 08/01/11 - 07/31/13

DESCRIPTION (provided by applicant): Renal cell therapy promises to improve the survival and overall health of patients suffering from acute renal failure (ARF), acute tubular necrosis (ATN), multiple organ failure (MOF), sepsis, cardiorenal syndrome (CRS) and end stage renal disease (ESRD). To this end, therapeutic biological devices addressing...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 09/01/10 - 07/31/11

DESCRIPTION (provided by applicant): Renal cell therapy promises to improve the survival and overall health of patients suffering from acute renal failure (ARF), acute tubular necrosis (ATN), multiple organ failure (MOF), sepsis, cardiorenal syndrome (CRS) and end stage renal disease (ESRD). To this end, therapeutic biological devices addressing...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-280
Budget: 04/01/10 - 03/31/11

DESCRIPTION (provided by applicant): Tissue engineering and cell therapy is a new and exciting approach to the treatment of acute and chronic diseases. The potential success of this therapeutic approach lies in the growing appreciation that most disease processes are not due to the lack of a single protein but develop due to alterations in compl...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-280
Budget: 09/01/09 - 02/28/11

DESCRIPTION (provided by applicant): Tissue engineering and cell therapy is a new and exciting approach to the treatment of acute and chronic diseases. The potential success of this therapeutic approach lies in the growing appreciation that most disease processes are not due to the lack of a single protein but develop due to alterations in compl...

Load More